Publications by authors named "Lisa Rafkin"

Claim this Profile
U
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Giacomo Lanzoni, Elina Linetsky, Diego Correa, Shari Messinger Cayetano, Roger A Alvarez, Lisa Rafkin

Stem Cells Transl Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials.
Jay M Sosenko, Jay S Skyler, Kevan C Herold, Desmond A Schatz, Michael J Haller, Lisa E Rafkin

Diabetes· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236.
Emily K Sims, Susan Geyer, Suzanne Bennett Johnson, Ingrid Libman, Laura M Jacobsen, Lisa E Rafkin

Diabetes Care· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention.
Emily K Sims, Susan Geyer, Suzanne Bennett Johnson, Ingrid Libman, Laura M Jacobsen, Lisa E Rafkin

Diabetes Care· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes.
Heba M Ismail, Carmella Evans-Molina, Linda A DiMeglio, Dorothy J Becker, Ingrid Libman, Lisa Rafkin

Pediatr Diabetes· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1.
Jay M Sosenko, Susan Geyer, Jay S Skyler, Lisa E Rafkin, Heba M Ismail

Pediatr Diabetes· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787.
Jay M Sosenko, Jay S Skyler, Jeffrey Mahon, Jeffrey P Krischer, Craig A Beam, Lisa E Rafkin

Diabetes Care· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes.
Polly J Bingley, Diane K Wherrett, Ann Shultz, Lisa E Rafkin, Mark A Atkinson

Diabetes Care· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: A Feasibility Study.
Polly J Bingley, Lisa E Rafkin, Della Matheson, Andrea K Steck, Liping Yu

Diabetes Technol Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.
Jay M Sosenko, Jay S Skyler, Craig A Beam, David Boulware, Jeffrey L Mahon, Lisa E Rafkin

Diabetes Care· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.
Jay M Sosenko, Jay S Skyler, Linda A DiMeglio, Craig A Beam, Jeffrey P Krischer, Lisa E Rafkin

Diabetes Care· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.
Jay M Sosenko, Jay S Skyler, Jeffrey Mahon, Jeffrey P Krischer, Carla J Greenbaum, Lisa E Rafkin

Diabetes Care· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.
Jay M Sosenko, Jay S Skyler, Craig A Beam, Jeffrey P Krischer, Carla J Greenbaum, Lisa E Rafkin

Diabetes· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.
Jay M Sosenko, Jay S Skyler, Jerry P Palmer, Jeffrey P Krischer, Liping Yu, Lisa Rafkin

Diabetes Care· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes.
Jay M Sosenko, Jay S Skyler, Jeffrey Mahon, Jeffrey P Krischer, Craig A Beam, Lisa E Rafkin

Diabetes Care· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study.
Jay M Sosenko, Jay S Skyler, Jeffrey Mahon, Jeffrey P Krischer, Craig A Beam, Lisa E Rafkin

Diabetes Care· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants.
Jay M Sosenko, Jeffrey Mahon, Lisa Rafkin, John M Lachin, Heidi Krause-Steinrauf

Pediatr Diabetes· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1).
Jay M Sosenko, Jay S Skyler, Jeffrey P Krischer, Carla J Greenbaum, Jeffrey Mahon, Lisa E Rafkin

Diabetes· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants.
Jay M Sosenko, Jerry P Palmer, Lisa E Rafkin, Jeffrey P Krischer, David Cuthbertson

Diabetes Care· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis